BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37657771)

  • 21. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
    Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
    Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.
    Dibas A; Rhiel M; Patel VB; Andrieux G; Boerries M; Cornu TI; Alzubi J; Cathomen T
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.
    Yu T; Luo C; Zhang H; Tan Y; Yu L
    Front Immunol; 2023; 14():1139482. PubMed ID: 37449207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo.
    Luo Z; Shi J; Jiang Q; Yu G; Li X; Yu Z; Wang J; Shi Y
    Mol Biomed; 2023 Mar; 4(1):8. PubMed ID: 36871129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
    Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
    Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
    Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.
    Tang L; Zhang H; Zhou F; Wei Q; Du M; Wu J; Li C; Luo W; Zhou J; Wang X; Chen Z; Zhang Y; Huang Z; Wu Z; Wen Y; Jiang H; Liao D; Kou H; Xiong W; Mei H; Hu Y
    Cancer Commun (Lond); 2024 Mar; 44(3):408-432. PubMed ID: 38407943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-21 Selectively Protects CD62L
    Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
    J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.
    Jamali A; Ho N; Braun A; Adabi E; Thalheimer FB; Buchholz CJ
    EMBO Mol Med; 2024 Apr; 16(4):784-804. PubMed ID: 38514793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
    Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
    Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
    Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
    Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
    Pennell CA; Barnum JL; McDonald-Hyman CS; Panoskaltsis-Mortari A; Riddle MJ; Xiong Z; Loschi M; Thangavelu G; Campbell HM; Storlie MD; Refaeli Y; Furlan SN; Jensen MC; Kean LS; Miller JS; Tolar J; Osborn MJ; Blazar BR
    Mol Ther; 2018 Jun; 26(6):1423-1434. PubMed ID: 29735365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo.
    Ye X; Liu M; Lv C; Li Y; Chen L; Zhang J; Mu J; Deng Q
    Technol Cancer Res Treat; 2022; 21():15330338221133224. PubMed ID: 36254554
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.